Compare BNBX & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNBX | SXTP |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | 26 | 3 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | BNBX | SXTP |
|---|---|---|
| Price | $0.52 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | ★ 375.2K | 195.7K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $253.12 | $33.92 |
| Revenue Next Year | N/A | $51.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.34 |
| 52 Week High | $6.17 | $8.62 |
| Indicator | BNBX | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 30.56 | 41.99 |
| Support Level | N/A | $1.27 |
| Resistance Level | $0.82 | $1.84 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 12.23 | 3.75 |
BNB Plus Corp focuses on digital asset treasury management of BNB. The group is unlocking institutional-grade access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company's differentiated blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.